Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070655 | 0.89 | MEN1 (0.43) | MEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL13113094 | 0.88 | — | — | |
| SCHEMBL1741851 | 0.87 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL3084829 | 0.87 | SMN1; SMN2 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL28647169 | 0.87 | ALDH1A1 (0.37) | MEN1KMT2A | |
| SCHEMBL24461929 | 0.87 | SMN1; SMN2 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL24461915 | 0.87 | SMN1; SMN2 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL24461912 | 0.87 | SMN1; SMN2 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL3071899 | 0.87 | SMN1; SMN2 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2HIF1A | |
| SCHEMBL3063054 | 0.87 | SMN1; SMN2 (0.47) | MEN1CYP1A2KMT2ASMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012036392-A3 | HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING THE SAME | 주식회사 아이지세라피 (KR) | 2012-05-10 | — | — | WO | claimed |
| EP-1930376-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2011-12-07 | — | — | EP | claimed |
| US-20260053136-A1 | SANITIZING AND DISINFECTING COMPOSITIONS WITH DWELL TIME INDICATORS AND CLEANING ARTICLES CONTAINING THE SAME | KIMBERLY CLARK CO (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4692247-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022211-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-01-22 | — | — | US | disclosed |
| EP-4180482-B1 | MOISTURE-CURABLE COMPOSITION | NITTO KASEI CO LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-4656672-A1 | METHOD FOR PRODUCING CURABLE COMPOSITION | Kaneka Corporation (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | NITTO KASEI CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4174053-B1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | NITTO KASEI CO LTD (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4569023-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025111365-A1 | METHOD OF PREPARING A MOISTURE CURABLE RESIN COMPOSITION WITH A NON-TIN CATALYST | KANEKA AMERICAS HOLDING, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| US-20040016363-A1 | CORROSION-INHIBITING COATING | VENTURE LENDING & LEASING, IV, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2004009869-A2 | CORROSION-INHIBITING COATING FOR METAL SURFACES | UNIVERSITY OF DAYTON (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-1325777-A1 | ABSORBENTS AND PROCESS FOR PRODUCING THE SAME, ABSORBABLE CONSTRUCTS AND ABSORBABLE ARTICLES | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-20030078349-A1 | For use in paper diaper, a physiological napkin, a pad, a paper towel | TAGAWA DAISUKE (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1275669-A1 | CROSSLINKED POLYMER, PROCESS FOR PRODUCING THE SAME, ABSORBENT STRUCTURE, AND ABSORBENT ARTICLE | SANYO CHEMICAL INDUSTRIES, Ltd. (JP) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | KDM2B, SETDB1, ASH2L | MEN1 684/4885CYP1A2 512/4885KMT2A 150/4885 |
| US-20260053136-A1 | SANITIZING AND DISINFECTING COMPOSITIONS WITH DWELL TIME INDICATORS AND CLEANING ARTICLES CONTAINING THE SAME | CUTA, SURF4, SDC1 | MEN1 1922/4885CYP1A2 2126/4885KMT2A 2899/4885 |
| US-20260022211-A1 | CURABLE COMPOSITION | H1-4, H1-0, H1-2 | MEN1 345/4885CYP1A2 3772/4885KMT2A 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.